
- /
- Supported exchanges
- / US
- / DARE.NASDAQ
Dare Bioscience Inc (DARE NASDAQ) stock market data APIs
Dare Bioscience Inc Financial Data Overview
Daré Bioscience, Inc., a biopharmaceutical company, develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert for the treatment of cervical intraepithelial neoplasia and other human papillomavirus related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-GML, a multi-target antimicrobial agent. Daré Bioscience, Inc. is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Dare Bioscience Inc data using free add-ons & libraries
Get Dare Bioscience Inc Fundamental Data
Dare Bioscience Inc Fundamental data includes:
- Net Revenue: 25 909
- EBITDA: -21 820 472
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dare Bioscience Inc News

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue...


Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation
Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path approach for its proprietary Sildenafil ...

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash fl...

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management Essentially all cervi...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.